Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trialChiara Cremolini, Federica Marmorino, Roberta Grande et al.|The Lancet Oncology|2020Cited by 322
Regorafenib for Patients with Metastatic Colorectal Cancer Who Progressed After Standard Therapy: Results of the Large, Single-Arm, Open-Label Phase IIIb CONSIGN StudyEric Van Cutsem, Alberto Zaniboni, Erika Martinelli et al.|The Oncologist|2018Cited by 143
Immune-Checkpoint Inhibitors in Advanced Bladder Cancer: Seize the DayBrigida Anna Maiorano, Evaristo Maiello|Biomedicines|2022Cited by 27
High Rates of Hidden HCV Infections among Hospitalized Patients Aged 55–85Annarita Valeria Piazzolla, Alessandra Mangia, Giulia Paroni et al.|Pathogens|2021Cited by 10
Author Index Vol. 77, Suppl. 1, 2009Antônio Rossi, Sabino De Placido, Domenico Galetta et al.|Oncology|2009Cited by 0